Laurus Labs Share Price Target 2025, 2026, 2030, 2040, 2050
Laurus Labs Limited was founded in 2005 in Hyderabad, India, as a pharmaceutical company specializing in the treatment of cancer, HIV/AIDS, heart disease, and stomach problems. Laurus supports drug development from early stage to large-scale production to ensure high-quality medicines for global healthcare needs.
This blog will provide the details of Laurus Labs Share Price targets as far as 25 years from now (2025 – 2050) based on its fundamentals, market position, and growth potential.
What is Laurus Labs Ltd NSE: LAURUSLABS?
Laurus Labs generates revenue from most of its sales with Active Pharmaceutical Ingredients (APIs), ready-to-use drugs, and biotechnological solutions. Laurus manufactures specialty products for global pharmaceutical companies and animal health and agrochemical products and maintains a global presence by investing in research facilities to faster growth and innovation.
Fundamental Data
| Metric | Value |
|---|---|
| Market Cap | ₹28,119 Cr. |
| 52-Week High / Low | ₹646 / ₹372 |
| Stock P/E | 141 |
| Book Value | ₹76.7 |
| Dividend Yield | 0.15% |
| ROCE | 6.60% |
| ROE | 3.97% |
| Face Value | ₹2.00 |
| Industry P/E | 28.8 |
| Net Cash Flow (PY) | ₹-29.7 Cr. |
| PBT (Annual) | ₹236 Cr. |
| EPS | ₹3.71 |
| Promoter Holding | 27.6% |
| PEG Ratio | 12.4 |
| Net Profit | ₹201 Cr. |
| Debt | ₹2,789 Cr. |
| Last Year Dividend | ₹43.1 Cr. |
| Current Liabilities | ₹3,459 Cr. |
| Current Assets | ₹4,120 Cr. |
| 5-Year ROE Variation | -8.56% |
| Debt to Equity | 0.67 |
| Price to Book Value | 6.80 |
| Graham Number | ₹80.0 |
Peer Comparisons
| S.No. | Company | P/E | Market Cap (₹ Cr.) | Div. Yield (%) | Quarterly Profit (₹ Cr.) | Qtr Profit Var (%) | Quarterly Sales (₹ Cr.) | Qtr Sales Var (%) | ROCE (%) |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Sun Pharma | 33.45 | 3,94,390.69 | 0.82 | 2,912.98 | 22.66 | 13,675.46 | 10.46 | 17.32 |
| 2 | Cipla | 23.93 | 1,19,183.64 | 0.88 | 1,574.59 | 31.37 | 7,072.97 | 7.10 | 22.80 |
| 3 | Dr. Reddy’s Labs | 17.92 | 96,111.27 | 0.69 | 1,404.20 | 1.69 | 8,381.20 | 15.81 | 26.53 |
| 4 | Mankind Pharma | 49.67 | 96,037.97 | 0.00 | 416.38 | -10.01 | 2,396.57 | 8.48 | 24.57 |
| 5 | Zydus Lifesciences | 19.65 | 89,086.93 | 0.34 | 1,026.20 | 33.34 | 5,269.10 | 16.96 | 22.34 |
| 6 | Lupin | 30.32 | 86,975.61 | 0.42 | 858.86 | 39.48 | 5,767.71 | 10.97 | 15.72 |
| 7 | Aurobindo Pharma | 18.39 | 65,340.94 | 0.40 | 845.57 | -9.69 | 7,978.52 | 8.53 | 14.10 |
| 8 | Laurus Labs | 140.83 | 28,119.32 | 0.15 | 92.94 | 298.88 | 1,415.05 | 18.42 | 6.60 |
| Period | Share Price (INR) |
|---|---|
| Before 1 Year | ₹398.55 |
| Before 6 Months | ₹447.90 |
| Before 5 Years | ₹83.70 |
| All-Time Max | ₹707.26 |
The company is a respected pharmaceutical company known for developing life-saving drugs. Due to the high price-earnings ratio (P/E) and the fluctuating share price performance, there may be ups and downs in the share price tomorrow. The price may fluctuate tomorrow, but the long-term growth potential remains strong.
| Day | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| Tomorrow | -26 from today’s price | +33 from today’s price |
LAURUSLABS Indicator Based Technical Analysis
NOTE!
Signals may differ across timeframes. If you’re planning to purchase LAURUSLABS and keep it for more than one week, it’s suggested that you choose signals from weekly and daily timeframes. For trading in the short term, signals that range from 5 minutes to 1-hour timeframes are better appropriate.
The company is an established pharmaceutical company with expertise in Active Pharmaceutical Ingredients (API), CRAMSA and ARV drugs. Expansion into contract manufacturing, oncology drugs, biotech solutions and new global contracts will strengthen the company’s position in the industry and support further growth.
Our analysis shows that the share price is expected to be between Rs 330 and Rs 750.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2025 | 330 | 750 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| January | 400 | 600 |
| February | 380 | 650 |
| March | 350 | 500 |
| April | 330 | 480 |
| May | 370 | 520 |
| June | 390 | 540 |
| July | 500 | 620 |
| August | 530 | 670 |
| September | 550 | 700 |
| October | 580 | 720 |
| November | 620 | 740 |
| December | 680 | 750 |
By 2026, The company will grow significantly and expand in areas such as pharmaceutical research and development (R&D), API manufacturing and biotech innovation. The entry into agrochemical contract manufacturing will also open up new revenue streams; the focus on international markets and regulatory approvals promises further expansion of the business.
Our analysis shows that the share price is expected to be between Rs 450 and Rs 1150.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2026 | 450 | 1150 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| January | 500 | 720 |
| February | 480 | 770 |
| March | 460 | 680 |
| April | 450 | 650 |
| May | 500 | 750 |
| June | 550 | 800 |
| July | 650 | 900 |
| August | 700 | 980 |
| September | 750 | 1020 |
| October | 800 | 1060 |
| November | 900 | 1100 |
| December | 1000 | 1150 |
The company aims to become an industry leader in drug formulations, life sciences and speciality pharma manufacturing by 2030. Its growth in Europe, combined with strategic investments in biotechnology and enzyme-based pharmaceuticals, will continue to drive its success. At the same time, its strong patent portfolio, growing demand for essential medicines and focus on sustainability will play an essential role in its long-term expansion plans.
Our analysis shows that the share price is expected to be between Rs 850 and Rs 1755.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2030 | 850 | 1755 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| January | 900 | 1100 |
| February | 880 | 1150 |
| March | 850 | 1200 |
| April | 950 | 1250 |
| May | 1000 | 1300 |
| June | 1100 | 1400 |
| July | 1200 | 1500 |
| August | 1300 | 1600 |
| September | 1400 | 1650 |
| October | 1500 | 1700 |
| November | 1600 | 1730 |
| December | 1650 | 1755 |
The company is likely to emerge as an international pharmaceutical company by 2040, thanks to advances in AI-driven drug discovery, precision medicine and biomanufacturing that will strengthen its competitive advantage. Expansion into oncology, central nervous system (CNS) and next-generation healthcare solutions will further drive the company’s global presence.
Our analysis shows that the share price is expected to be between Rs 2755 and Rs 3365.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2040 | 2755 | 3365 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| January | 2755 | 2900 |
| February | 2780 | 2950 |
| March | 2800 | 3000 |
| April | 2850 | 3050 |
| May | 2900 | 3100 |
| June | 2950 | 3150 |
| July | 3000 | 3200 |
| August | 3050 | 3250 |
| September | 3100 | 3280 |
| October | 3150 | 3300 |
| November | 3200 | 3340 |
| December | 3250 | 3365 |
The company could become one of the leading biotech and pharmaceutical companies by 2050. Its focus on innovation, R&D investment, new drug development and long-term industry leadership should cement this status. Its business will encompass pharmaceuticals, biotechnology and contract research – ensuring Laurus Labs remains a major player in global healthcare.
Our analysis shows that the share price is expected to be between Rs 5975 and Rs 6855.
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2050 | 5975 | 6855 |
| Month | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| January | 5975 | 6100 |
| February | 6020 | 6180 |
| March | 6080 | 6250 |
| April | 6150 | 6320 |
| May | 6200 | 6400 |
| June | 6280 | 6480 |
| July | 6350 | 6550 |
| August | 6420 | 6620 |
| September | 6480 | 6680 |
| October | 6550 | 6725 |
| November | 6620 | 6800 |
| December | 6700 | 6855 |
| Year | Minimum Price (Rs) | Maximum Price (Rs) |
|---|---|---|
| 2025 | 330 | 750 |
| 2026 | 450 | 1150 |
| 2030 | 850 | 1755 |
| 2040 | 2755 | 3365 |
| 2050 | 5975 | 6855 |
| Shareholder Type | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|
| Promoters | 27.18% | 27.18% | 27.18% | 27.62% |
| FIIs | 25.98% | 25.67% | 26.08% | 25.56% |
| DIIs | 11.78% | 13.56% | 13.05% | 12.74% |
| Public | 35.07% | 33.59% | 33.69% | 34.09% |
Piramal Pharma Share Price Target 2025, 2026, 2030, 2040, 2050
Should I Buy Laurus Labs Stock?
The company promoters hold a stable share of around 27%, while FIIs hold a strong share of around 26%. The share of DIIs is increasing while the public share is decreasing. This shows that large investors have confidence in the company. If you’re thinking of buying, this is a good sign, but you should always do your research before investing.
Laurus Labs Ltd Earning Results (Financials)
| Year | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|
| Sales (₹ Cr) | 5,273 | 5,041 | 6,041 | 4,936 | 4,814 |
| Expenses (₹ Cr) | 4,397 | 4,261 | 4,448 | 3,512 | 3,262 |
| Operating Profit (₹ Cr) | 876 | 779 | 1,592 | 1,424 | 1,552 |
| OPM % | 17% | 15% | 26% | 29% | 32% |
| Other Income (₹ Cr) | 35 | 24 | 6 | 14 | 23 |
| Interest (₹ Cr) | 210 | 183 | 165 | 102 | 68 |
| Depreciation (₹ Cr) | 422 | 385 | 324 | 251 | 205 |
| Profit Before Tax (₹ Cr) | 279 | 236 | 1,109 | 1,084 | 1,301 |
| Tax % | – | 29% | 28% | 23% | 24% |
| Net Profit (₹ Cr) | 201 | 162 | 793 | 832 | 984 |
| EPS (₹) | 3.71 | 2.98 | 14.67 | 15.40 | 18.33 |
Expert Forecasts On The Future Laurus Labs Of Ltd.
The company’s sales and profit have gone up and down over the years. The latest numbers show lower profits and earnings per share (EPS). Expenses are high, and growth is slow. The stock might recover if the company improves its margins. Invest only if you trust its future plans.
Is Laurus Labs Stock Good to Buy? (Bull case & Bear case)
Bullish Case:
- Strong presence in the pharma and biotech sector.
- Global approvals (USFDA, WHO, etc.) ensure business stability.
- Increasing interest from institutional investors (FII & DII).
- Future growth potential in CDMO services.
Bearish Case:
- Declining profit margins and weak earnings.
- High debt burden.
- Valuation of the share is expensive (high P/E ratio).
- Slowdown in growth in core business.
Conclusion
Laurus Labs is an established player in the pharma and biotech industry, providing Active Pharmaceutical Ingredients (APIs), formulations, CDMO services and research solutions. Its robust production, R&D capabilities and expansion into areas such as agrochemicals and animal health make the company’s long-term growth look promising. Still, short-term issues such as declining profits and high debt make the investment uncertain. If you’re considering an investment, you should read the full article for details about the company’s performance and future stock projections.
Alembic Share Price Target 2025, 2026, 2030, 2040, 2050
